TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19001202

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg/d
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: Estrogen plus medroxyprogesterone acetate, 2.5 mg/d
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study: 17033273

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol tartrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: 25 mg carvedilol
Number of subjects: 12
Study: 12723464

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11095086

Group type: EXPERIMENTAL
Intervention: Betamethasone (n = 66)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (n = 71)
Number of subjects: 137
Study: 9055049

Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual community physician care
Number of subjects: 400
Study: 8229609

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) therapy, 8.5 +/- 0.85 gms before meals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (phototherapy only)
Number of subjects: 30
Study: 2985395

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (single s.c. dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 0
Study: 30207079

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) at high frequency (three times/week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) at high frequency (three times/week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) at low frequency (two times/week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) at low frequency (two times/week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 53
Study: 26663540

Group type: EXPERIMENTAL
Intervention: 1000 μg Chromium picolinate (CrP) for 6 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 85
Study: 25126867

Group type: EXPERIMENTAL
Intervention: 8 weeks interval training (60‐79% HRmax) programme of between 45 and 60 minutes
Number of subjects: 245

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 245
Study: 22410037

Group type: EXPERIMENTAL
Intervention: Rusch intubation stylet tied to the NGT (group S)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group C) - NGT inserted with patient's head in neutral position
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study: 20473540

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham pulsed electromagnetic field therapy (sham PEMF)
Number of subjects: 40
Study: 18360659

Group type: EXPERIMENTAL
Intervention: Periodontal initial therapy
Number of subjects: 30
Study: 16737046

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with high CD4 count (group 1A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with low CD4 count (group 1B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recombinant HBV vaccine (20 micrograms per dose) in normal healthy controls (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in all groups (HIV-positive and controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PHA stimulation in HIV-positive groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with high CD4 count
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with low CD4 count
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant HBV vaccine in patients with CD4 count < 50
Number of subjects: 60
Study: 12881821

Group type: EXPERIMENTAL
Intervention: Tetanic contractions (35Hz)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-Hz twitch contractions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1-Hz twitch contractions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inactive leg (control)
Number of subjects: 12
Study: 10688158

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both olanzapine and risperidone
Number of subjects: 36
Study: 8813311

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound measurement of bladder wall thickness greater than 5 mm
Number of subjects: 184

Group type: COMPARATOR
Intervention: Bladder wall thickness less than 3.5 mm
Number of subjects: 184
Study: 1881582

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody OKT3
Number of subjects: 65

Group type: COMPARATOR
Intervention: High-dose methylprednisolone
Number of subjects: 65
Study: 6348424

Group type: EXPERIMENTAL
Intervention: 2 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin followed by 3 days of oral cephalexin)
Number of subjects: 160
Study: 30289491

Group type: EXPERIMENTAL
Intervention: Phage cocktail (TM3 plus TM1, TM2, and TM4)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Single phage (TM3)
Number of subjects: 360

Group type: COMPARATOR
Intervention: 200 μL sterile PBS (control)
Number of subjects: 360

Group type: COMPARATOR
Intervention: 200 μL of selected phage (TM3) (control)
Number of subjects: 360
Study: 29863610

Group type: EXPERIMENTAL
Intervention: OctaplasLG
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard FFP
Number of subjects: 57
Study: 26977602

Group type: EXPERIMENTAL
Intervention: Planning-focused CBT (PML)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Solution-focused CBT (SFT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Both treatments (PML and SFT)
Number of subjects: 159
Study: 24119856

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nutritional education
Number of subjects: 73
Study: 21917299

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (quinapril, losartan, amlodipine, hydrochlorothiazide, or bisoprolol) for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Posttreatment changes
Number of subjects: 61
Study: 19433129

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 17157442

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments (EMA) of happiness
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Positive and Negative Affect Schedule (PANAS)
Number of subjects: 72
Study: 15036166

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 57
Study: 12471004

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micro g/kg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ramosetron 4 micro g/kg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 9796881

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (single dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg (once daily for 10 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (once daily for 10 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (once daily for 10 days)
Number of subjects: 21
Study: 7549418

Group type: EXPERIMENTAL
Intervention: Injection of Vasoactive Intestinal Polypeptide (VIP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Injection of Substance P (SP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methacholine-induced sweating
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flare responses to VIP and SP
Number of subjects: 20
Study: 2229528

Group type: EXPERIMENTAL
Intervention: Terbinafine (125 mg taken twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 628824

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy without pyloroplasty
Number of subjects: 64
Study: 31344386

Group type: EXPERIMENTAL
Intervention: Topical coal tar treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 17
Study: 30251749

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interfascial injection (US-IFI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ultrasound-guided nerve stimulating technique (US-NS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 62
Study: 27150460

Group type: EXPERIMENTAL
Intervention: Lactoferrin and lactoperoxidase-containing tablets
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study: 26187496

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200mg per day, up to 400mg if taking combined oral contraceptives)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 0
Study: 23528074

Group type: EXPERIMENTAL
Intervention: 10% PVP-I
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 1.25% PVP-I
Number of subjects: 241

Group type: COMPARATOR
Intervention: Iodine-free antiseptic
Number of subjects: 241
Study: 21511526

Group type: EXPERIMENTAL
Intervention: Passive distraction (ignoring tones)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active distraction (reacting to target tone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No distraction condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Other mental tasks (word association, mental subtraction, spatial navigation)
Number of subjects: 12
Study: 19702677

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 12921

Group type: COMPARATOR
Intervention: UFH plus GP IIb/IIIa inhibitor
Number of subjects: 12921
Study: 17365760

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,800 mg/day for 8 weeks
Number of subjects: 50
Study: 15231010

Group type: EXPERIMENTAL
Intervention: Oral daily ibandronate (2.5 mg)
Number of subjects: 2946

Group type: EXPERIMENTAL
Intervention: Oral intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946

Group type: COMPARATOR
Intervention: Oral ibandronate (daily and intermittent)
Number of subjects: 2946
Study: 11234783

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM) for women
Number of subjects: 383

Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR) for women
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM) for casual partners
Number of subjects: 383

Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR) for casual partners
Number of subjects: 383
Study: 9678620

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 5 years) in adjuvant studies
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 5 years) in chemoprevention study
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo in chemoprevention study
Number of subjects: 321
Study: 8053589

Group type: EXPERIMENTAL
Intervention: Mivacurium 30, 50, or 70 micrograms.kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rocuronium 100, 200, 250, or 300 micrograms.kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of rocuronium and mivacurium (1 ED50 rocuronium + 1 ED50 mivacurium, etc.)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms.kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Mivacurium 150 micrograms.kg-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rocuronium 300 micrograms.kg-1 + Mivacurium 75 micrograms.kg-1 (Group 4)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms.kg-1 + Mivacurium 150 micrograms.kg-1 (Group 5)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Number of subjects: 160
Study: 2903169

Group type: EXPERIMENTAL
Intervention: Idazoxan (40 mg, orally)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idazoxan (iv administration 20 min before GIT)
Number of subjects: 21
Study: 31578273

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICPIs)
Number of subjects: 0
Study: 29440887

Group type: EXPERIMENTAL
Intervention: Arformoterol 15 µg, twice daily
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Arformoterol responders
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 841
Study: 27027204

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25267385

Group type: EXPERIMENTAL
Intervention: External Facilitator (EF)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: External Facilitator plus Internal Facilitator (EF/IF)
Number of subjects: 1600
Study: 23502689

Group type: EXPERIMENTAL
Intervention: Online self-help cognitive behavioral therapy (CBT) package (Overcoming Bulimia Online)
Number of subjects: 8
Study: 19952780

Group type: EXPERIMENTAL
Intervention: Self-pressure group (n = 114)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Office pressure group (n = 114)
Number of subjects: 228
Study: 19069453

Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT) with aspirin (125 mg thrice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronotherapy (ChN) with aspirin taken once daily at 22.00
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 16809906

Group type: EXPERIMENTAL
Intervention: PSE/DAG (1.2 g PSE/30 g DAG for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAG mayonnaise (control)
Number of subjects: 0
Study: 14719295

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment in the treatment group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Drugs in the control group
Number of subjects: 46
Study: 11703280

Group type: EXPERIMENTAL
Intervention: 10‐s sustained freeze with liquid nitrogen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional freeze with liquid nitrogen
Number of subjects: 200
Study: 9208339

Group type: EXPERIMENTAL
Intervention: Incadronate (0.025-1.6 mg) in healthy volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incadronate (2.5-10.0 mg) in patients with malignancy-associated hypercalcemia
Number of subjects: 0
Study: 7956408

Group type: EXPERIMENTAL
Intervention: Simple saline solution nasal irrigation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Large particle water vapor at 43 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Molecular water vapor at 41 degrees C
Number of subjects: 30
Study: 2443363

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 306
Study: 29369166

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28698390

Group type: EXPERIMENTAL
Intervention: Walking Intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait List Control
Number of subjects: 62
Study: 25381344

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 24
Study: 22928476

Group type: EXPERIMENTAL
Intervention: AS(100)
Number of subjects: 0
Study: 21535040

Group type: EXPERIMENTAL
Intervention: Relaxation training using a 30-minute audio CD prior to the procedure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no relaxation training)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 61
Study: 18294083

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: extended-release mixed amphetamine salts (se-AMPH ER, 30 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16547619

Group type: EXPERIMENTAL
Intervention: MIVAP (Minimally Invasive Video-Assisted Parathyroidectomy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: OMIP (Open Minimally Invasive Parathyroidectomy)
Number of subjects: 60
Study: 12953736

Group type: EXPERIMENTAL
Intervention: Mothers of preterm infants (n=33)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mothers of full term normal infants (n=27)
Number of subjects: 60
Study: 10602721

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral cefaclor
Number of subjects: 67
Study: 9323621

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 8
Study: 31852538

Group type: EXPERIMENTAL
Intervention: Household visits only (Arm 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Small group discussions only (Arm 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of both (Arm 3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intervention (Arm 4)
Number of subjects: 48
Study: 30481742

Group type: EXPERIMENTAL
Intervention: Peptidomic identification of serum peptides using ultrafiltration and liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (non-GDM mothers)
Number of subjects: 200
Study: 27936169

Group type: EXPERIMENTAL
Intervention: Synbiotic (1.5 × 10^10 CFU Ecologic® 825 + 10 g fructo‐oligosaccharides (FOS P6) per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control supplements
Number of subjects: 20
Study: 24694748

Group type: EXPERIMENTAL
Intervention: Cobedding group (receiving care in the same incubator)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care group (receiving care in separate incubators)
Number of subjects: 100
Study: 22228607

Group type: EXPERIMENTAL
Intervention: dCIT‐TR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: dCIT
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 19225400

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once daily
Number of subjects: 664

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice daily
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once daily and twice daily
Number of subjects: 664
Study: 16840982

Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Betaject autoinjector
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Betaject Light autoinjector
Number of subjects: 294
Study: 15562775

Group type: EXPERIMENTAL
Intervention: estradiol velerate (E2V) 1.0 mg/d and medroxyprogestetone acetate (MPA) 2 mg/d
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 11279411

Group type: EXPERIMENTAL
Intervention: Partial inferior sternotomy (ministernotomy group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full median sternotomy (standard sternotomy group)
Number of subjects: 100
Study: 8989263

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean dose of 0.128 +/- 0.003 IU/kg.week for the first month, then 0.23 +/- 0.01 IU/kg.week, divided into daily doses (0.7-4.3 IU/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 20
Study: 7684225

Group type: EXPERIMENTAL
Intervention: Iloprost applied as an aqueous solution, hydrogels, and fatty ointment at dose levels of at least 50/25 ng/cm2 (intact/stripped skin)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Iloprost applied at high doses (400/150 ng/cm2)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Iloprost applied to large areas of skin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Iloprost applied at a dose of 25 micrograms/100 cm2 once daily for 60 days
Number of subjects: 73
Study: 2892260

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 197
Study: 29903020

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (RA and SA)
Number of subjects: 30
Study: 27448468

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PD+OSA
Number of subjects: 38